Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Stomach Neoplasms 2Carcinoma, Hepatocellular 2Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Esophageal Squamous Cell Carcinoma 1Digestive System Diseases 1Carcinoma 1Advanced Pancreatic Cancer 1

Interventions

Gemcitabine 11pembrolizumab 10Oxaliplatin 7Nivolumab 7Irinotecan 7Fluorouracil 7Capecitabine 7durvalumab 6Sorafenib 6Leucovorin 6Cyclophosphamide 6Paclitaxel 5Ipilimumab 5tislelizumab 3poly ICLC 3lenvatinib 3fludarabine 3Sunitinib 3Radiotherapy 3Cisplatin 3Cetuximab 3130-nm albumin-bound paclitaxel 3seocalcitol 2selinexor 2pemigatinib 2futuximab 2fludarabine phosphate 2donafenib 2cemiplimab 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × penpulimab × Gastrointestinal × Clear all
NCT05494060 2023-11-07

EXPLORING

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
80 enrolled
Gastrointestinal

Carcinoma, Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡